The National Institutes of Health will phase out its support of the clinical practice guidelines that advise doctors how to diagnose and treat HIV.

Yeztugo, approved by the FDA, was highly effective in two randomized trials. It costs $28,218 per year, and people have to be ...

The Food and Drug Administration approved the preventative use of lenacapavir, made by Gilead Sciences, on Wednesday. Experts ...

Researchers from MIT and Scripps have unveiled a promising new HIV vaccine approach that generates a powerful immune response ...

The U.S. has approved the world’s only twice-a-year shot to prevent HIV, the first step in an anticipated global rollout that ...

Clinical trials have shown that six-monthly injections of lenacapavir are almost 100 percent protective against becoming ...

Yeztugo, a twice-a-year antiviral shot to prevent HIV, was approved by the Food and Drug Administration on Wednesday, marking ...

More than 460 laid-off employees at the nation's top public health agency received notices Wednesday that they are being ...

In the aftermath of a broad consolidation of the CDC, health experts are voicing patient safety concerns for chronic disease patients, according to a June 11 NBC News report.  Experts expressed alarm ...

In a recent decision, the Centers for Disease Control and Prevention (CDC) abruptly eliminated $200,000 in annual HIV ...

Organizations helping end the stigma around HIV all across Kentucky said federal funding cuts could affect testing and other ...